Billionaire Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen


Warren Buffett

NEW YORK: Billionaire Warren Buffett's (pic) Berkshire Hathaway Inc said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co spinoff, Organon & Co.

In the second quarter, Berkshire said it exited a $180 million stake in Biogen Inc and reduced investments in Abbvie Inc, Bristol-Myers Squibb Co and Merck.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Wasco debuts Asean sustainable finance framework
KIP-REIT buys retail asset in Perak
Jakarta fears labour law refit will impact fund flows
Stronger second half seen for Hap Seng Plantations
Senate probes unauthorised transactions
Vietnam lauds benefits of WTO membership
MAA projects vehicle sales to hit 800,000 in 2024
MISC’s net profit slips to RM339mil in 3Q
New contracts to drive Dayang’s profit
Govt monitoring AI use in human-resource sector

Others Also Read